Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  protein tyrosine kinase >  Tepotinib

Tepotinib

Basic information Safety Supplier Related

Tepotinib Basic information

Product Name:
Tepotinib
Synonyms:
  • CS-977
  • EMD 1214063; EMD1214063
  • 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile
  • epotinib(EMD 1214063)
  • Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]
  • 3-(1-(3-(5-((1-Methylpiperidin-4-yl)Methoxy)pyriMidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile
  • EMD-1214063
  • 3-(1-(3-(5-((1-METHYLPIPERIDIN-4-YL)METHOXY)PYRIMIDIN-2-YL)BENZYL)-1,6-DIHYDRO-6-OXOPYRIDAZIN-3-YL)B
CAS:
1100598-32-0
MF:
C29H28N6O2
MW:
492.57
Product Categories:
  • Inhibitors
  • API
Mol File:
1100598-32-0.mol
More
Less

Tepotinib Chemical Properties

Boiling point:
626.5±65.0 °C(Predicted)
Density 
1.25
storage temp. 
Store at -20°C
pka
8.93±0.10(Predicted)
Water Solubility 
≥ 4.93 mg/mL in DMSO, <2.52 mg/mL in EtOH, <2.56 mg/mL in Water
InChI
InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3
InChIKey
AHYMHWXQRWRBKT-UHFFFAOYSA-N
SMILES
C(#N)C1=CC=CC(C2=NN(CC3=CC=CC(C4=NC=C(OCC5CCN(C)CC5)C=N4)=C3)C(=O)C=C2)=C1
More
Less

Tepotinib Usage And Synthesis

Description

Tepotinib is a highly selective inhibitor against MET. In xenograft models, acquired resistance to EGFR TKIs via secondary EGFR T790 M mutations can be overcome with tepotinib treatment.

Uses

EMD 1214063 is a novel ATP-comptetitive inhibitor of the MET hepatocyte growth factor receptor and a novel kinase inhibitor and a therapeutic agent for neuroblastoma. Potent c-MET inhibitor.

Mechanism of action

Tepotinib is a Kinase Inhibitor. The mechanism of action of tepotinib is as a Mesenchymal Epithelial Transition Inhibitor, and P-Glycoprotein Inhibitor.

Pharmacology

Tepotinib is a highly-selective inhibitor of MET kinase activity, with an average IC50 of approximately 1.7 nmol/L. It has a moderate duration of action necessitating once-daily administration.  Tepotinib has been associated with the development of interstitial lung disease (ILD)/pneumonitis, which can sometimes be fatal. Patients should be monitored closely for signs of new or worsening respiratory symptoms (e.g. dyspnea, cough), and treatment with tepotinib should be immediately withheld if ILD/pneumonitis is suspected. If no other potential causes of ILD/pneumonitis are identified, therapy with tepotinib should be suspended indefinitely.

Clinical Use

Tepotinib is currently being evaluated in combination with EGFR TKI gefitinib and also a separate trial in NSCLC patients with MET exon 14 skipping mutation and MET amplification.

Side effects

  • anxiety
  • chest pain or tightness
  • difficult or labored breathing
  • dizziness or lightheadedness
  • fast heartbeat
  • fever or chills
  • general feeling of discomfort or illness
  • muscle or bone pain

Synthesis

The synthesis of Tepotinib is as follows:
Acetonitrile (700 ml) was added to the reaction vessel, and the compound represented by formula 7a (37.63 g, 0.1 mol), the compound represented by formula 8 (23.66 g, 0.12 mol), and potassium carbonate (34.55 g, 0.25 mol) were added under stirring.and tetrabutylammonium bromide (1.93g, 0.006mol), the reaction system was stirred and heated to reflux, and the reaction was stirred at reflux for 12h. After the reaction was completed, the temperature was cooled to room temperature, the reaction solution was concentrated under reduced pressure to dryness, and ethanol (360ml) was added. ), stir to dissolve, slowly add 1.5 mol/l hydrochloric acid aqueous solution dropwise, adjust the pH value to 1-2, cool down to 5-7 °C, stir and crystallize for 6 h, filter, and vacuum dry the solid at 45 °C for 6 h to obtain formula 1. The compound (44.42 g) was shown in a yield of 81.2% and a purity of 99.7% by HPLC.

Drug interactions

Tepotinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have mesenchymal-epithelial transition (_MET_) exon 14 skipping alterations.

Metabolism

Tepotinib is metabolized primarily by CYP3A4 and CYP2C8, with some apparent contribution by unspecified UGT enzymes. The metabolite M506 is the major circulating metabolite, comprising approximately 40.4% of observed drug material in plasma, while the M668 glucuronide metabolite has been observed in plasma at much lower quantities (~4% of an orally administered dose). A total of 10 phase I and phase II metabolites have been detected following tepotinib administration, most of which are excreted in the feces.

TepotinibSupplier

Suzhou Ryan Pharmaceutical Technology Co., Ltd. Gold
Tel
0512-68780025,68780026 18962125825
Email
sales@ryanchem.com
Anqing Benro pharmachem Technology Co.,Ltd. Gold
Tel
05565209906 15391842992
Email
794263564@qq.com
Shanghai Famo Bio-chemical Technology Company Ltd. Gold
Tel
021-36680027 15800370750
Email
1706640024@qq.com
Chunchuang (Wuhan) Technology Co., Ltd Gold
Tel
15342225168
Email
yutianchun2007@126.com
WuHu Linze pharmaceutical Co.,Ltd. Gold
Tel
0553-0553-5802116 18356571950
Email
2592492800@qq.com